Lantibiotic production is a burden for the producing staphylococci

Scientific Reports
Patrick EbnerF Gotz

Abstract

Lantibiotics are antimicrobial peptides that contain non-proteinogenic amino acids lanthionine and 3-methyllanthionine and are produced by Gram-positive bacteria. Here we addressed the pros and cons of lantibiotic production for its producing strains. Two staphylococcal strains, S. gallinarum Tü3928 and S. epidermidis Tü3298 producing gallidermin and epidermin respectively were selected. In each of these parental strains, the structural genes gdmA and epiA were deleted; all the other biosynthetic genes including the immunity genes were left intact. Comparative analysis of the lantibiotic-producing strains with their non-producing mutants revealed that lantibiotic production is a burden for the cells. The production affected growth, caused release of ATP, lipids and increased the excretion of cytoplasmic proteins (ECP). The epidermin and gallidermin immunity genes were insufficient to protect the cells from their own product. Co-cultivation studies showed that the ΔgdmA mutant has an advantage over the parental strain; the latter was outcompeted. On the one hand, the production of staphylococcal lantibiotics is beneficial by suppressing competitors, but on the other hand they impose a burden on the producing-strains when they ac...Continue Reading

References

Feb 1, 1990·Applied Microbiology and Biotechnology·T HörnerG Jung
Oct 15, 1988·European Journal of Biochemistry·R KellnerF Götz
May 1, 1988·The Journal of Antibiotics·H KinashiC R Hutchinson
Aug 1, 1966·Canadian Journal of Microbiology·F Sala, D W Westlake
Oct 1, 1980·Archives of Microbiology·P ReisingerW P Hammes
Apr 1, 1983·Proceedings of the National Academy of Sciences of the United States of America·P J YoungmanR Losick
May 1, 1981·Antimicrobial Agents and Chemotherapy·B Hartman, A Tomasz
Jul 1, 1993·Applied and Environmental Microbiology·B GraviusJ Cullum
Apr 18, 2002·Current Drug Targets·Dzung B Diep, Ingolf F Nes
Apr 26, 2002·Trends in Microbiology·Mark J Pallen
Mar 30, 2006·Antimicrobial Agents and Chemotherapy·Raquel Regina BonelliImke Wiedemann
May 18, 2007·Annual Review of Microbiology·Joanne M Willey, Wilfred A van der Donk
Jul 28, 2009·Journal of Bacteriology·Lalitha BiswasFriedrich Götz
Oct 22, 2009·Natural Product Reports·Markus NettBradley S Moore
Jan 29, 2010·Molecular Microbiology·Martin SchlagFriedrich Götz
Sep 2, 2010·Microbiology and Molecular Biology Reviews : MMBR·Ju-Hoon Lee, Daniel J O'Sullivan
Mar 15, 2011·Journal of Bacteriology·Nouri L Ben ZakourJ Ross Fitzgerald
Mar 22, 2012·Microbial Drug Resistance : MDR : Mechanisms, Epidemiology, and Disease·Anna MüllerTanja Schneider
Oct 15, 2013·International Journal of Medical Microbiology : IJMM·Friedrich GötzMartin Schlag
May 27, 2015·Molecular Microbiology·Patrick EbnerFriedrich Götz
Mar 1, 2016·BMC Genomics·Gitte J M ChristensenHolger Brüggemann
Mar 24, 2016·Infection and Immunity·Patrick EbnerFriedrich Götz
Oct 25, 2016·Nature Microbiology·Vera PaderAndrew M Edwards
Aug 10, 2017·Cell Reports·Patrick EbnerFriedrich Götz

❮ Previous
Next ❯

Citations

Nov 1, 2020·Applied Microbiology and Biotechnology·Maria do Carmo de Freire BastosMarcus Lívio Varella Coelho

❮ Previous
Next ❯

Methods Mentioned

BETA
Enzymatic assay
PCR
Assay

Software Mentioned

GraphPad Prism
Epis
ImageJ
Gdm

Related Concepts

Related Feeds

CRISPR & Staphylococcus

CRISPR-Cas system enables the editing of genes to create or correct mutations. Staphylococci are associated with life-threatening infections in hospitals, as well as the community. Here is the latest research on how CRISPR-Cas system can be used for treatment of Staphylococcal infections.